Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat vs Best Available Therapy in Polycythemia Vera
NCT07722611Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Jun 2032
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bomedemstat in polycythemia vera (PV) (2 arms), sponsored by Merck & Co. Primary endpoint: Clinicohematologic Response Rate at 52 weeks. Started Oct 2026; status: recruiting.
02
Drugs
bomedemstat
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT07722611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722611.